...Li Zhou; Zhe Shan; Jiangsha Fan Introduction: Acute lymphoblastic leukemia (ALL) is a common hematologic neoplastic disease. This study discussed the effect of extracellular vesicles (EVs) released from bone marrow mesenchymal stem cells (BMSCs) on ALL cells and the mechanism. Methods: BMSCs-EVs...

... and refractory acute lymphoblastic leukemia (ALL) than conventional chemotherapy. But, blinatumomab suppresses humoral immunity due to long-lasting B-cell depletion during and after the treatment. The development of PML involves cellular immunity and impairment of humoral immunity. Although few cases...

...) molecule, was evaluated in an expansion cohort of the phase 1b/2 study (NCT02412306) in Japanese adult ( n = 14) and pediatric ( n = 17) patients with relapsed/refractory Philadelphia-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). Materials and methods: Globally recommended...

... is very rare and mostly fatal. Treatment recommendations for such a complication are not yet established. Here, we report the dramatic recovery of HLH/MAS following tisagenlecleucel infusion in a young patient with relapsed acute lymphoblastic leukemia using etoposide phosphate (EP). We propose...

...Elena Parovichnikova; Vera Troitskaya; Andrey Sokolov; Olga Gavrilina; Zalina Akhmerzaeva; Larissa Kuzmina; Galina Kliasova; Julia Chabaeva; Sergey Kulikov; Sergey Bondarenko; Olga Baranova; Olga Samoilova; Kamil Kaplanov; Natalia Minaeva; Valeriy Savchenko; Russian Acute Lymphoblastic Leukemia...

...Firas El Chaer; Noa G. Holtzman; Edward A. Sausville; Jennie Y. Law; Seung Tae Lee; Vu H. Duong; Maria R. Baer; Rima Koka; Zeba N. Singh; Nancy M. Hardy; Ashkan Emadi Adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with conventional chemotherapy have...

...Boaz Nachmias; Adir Shaulov; Moshe E. Gatt; Michael Shapira; Alexander Gural The treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) presents a true clinical challenge. In 2012, a protocol combining bortezomib, dexamethasone, asparaginase, doxorubicin, and vincristine...

...Ruham Alshiekh-Nasany; Dan Douer Introduction: Similar to pediatric regimens, multiple doses of L -asparaginase (PEG-Asp) are being increasingly used in adults with newly diagnosed acute lymphoblastic leukemia (ALL) with promising results. One of the most common side effects of the drug in adults...

...Patrick W. Burke; Dan Douer The cure rate of acute lymphoblastic leukemia (ALL) in children is 80%, compared to less than half in adults. A major proportion of this cure rate drop occurs in adolescents and young adults (AYAs). The age range defining this population varies between studies...

... is a conventional agent for relapsed or refractory acute lymphoblastic leukemia (ALL). However, an effective combination with other drugs and a feasible dosage has not been identified. A retrospective study of 46 patients with relapsed or refractory ALL was conducted to determine the efficacy of mitoxantrone...

... the phenotypic signature of T cells present at diagnosis in 39 pediatric patients with acute lymphoblastic leukemia (ALL) treated within standardized ALL-BFM study protocols. Previously described age associations of lymphocyte subpopulations in the peripheral blood of healthy children were reproduced in leukemic...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Precursor B cell Acute lymphoblastic leukemia Immunophenotype Surface...

... Acute lymphoblastic leukemia Molecular mechanism Bortezomib Acute lymphocytic leukemia (ALL) is a malignant disorder that originates from one single hematopoietic precursor committed to the B cell or T cell lineage; 80–85% of ALL are of B-cell lineage (B cell precursor ALL, BCP-ALL) and 15...

... could suggest increased expression of HERV-K in leukemic cells. To elucidate the role of endogenous retroviruses in leukemogenesis, studies were undertaken to assess env gene expression of HERV-K and HERV-W in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Results...

... risk for developing acute lymphoblastic leukemia and acute myeloid leukemia (AML). Case Report: A 33-year-old male XP patient was diagnosed with acute megakaryoblastic leukemia with a complex karyotype. He received standard induction chemotherapy with cytarabine and daunorubicin. After the first cycle...

... to in the content or advertisements. Acute lymphoblastic leukemia Leukemogenesis Poor prednisolone response URG4 Acute lymphoblastic leukemia (ALL) is the most common childhood malignant disease. Variations in the expression level of the cell cycle genes including cyclins, cyclin-dependent...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Acute lymphoblastic leukemia Chromosomal translocation Karyotyping...

... with acute lymphoblastic leukemia (ALL) can result from the disease itself, from treatment, or from other conditions (e.g. sepsis). The aim of this study was to determine the levels of markers of endothelial activation in children with ALL and to assess their potential prognostic value. Fifty-two children...

...Reyad Dada; Stefan Wilop; Edgar Jost; Oliver Galm; Nikolaus Gassler; Rainhardt Osieka Infiltration of the liver with consecutive severe dysfunction is rarely seen in adult acute lymphoblastic leukemia (ALL). We describe a case of a 32-year-old woman with severe icterus, thrombocytopenia...

...Mehmet Akif Ozdemir; Musa Karakukcu; Turkan Patiroglu; Yasemin Altuner Torun; Mehmet Kose Introduction: The standard management of childhood acute lymphoblastic leukemia with hyperleukocytosis is unclear and its treatment has focused on prompt leukocytoreduction. Cytoreductive therapies have been...